Talawar Therapeutics is a biotechnology company developing potentially best-in-class bispecific antibodies that pair independent disorder drivers in a single therapy, targeting pathways that work together for greater, more durable impact. Our lead program, TALA-125, is a novel anti-IL-13 x anti-IL-18 bispecific that combines two clinically validated, largely orthogonal mechanisms designed to shatter the current limitations of existing treatments – with broad applicability across first-line patients and those who have failed previous therapies.

Talawar Therapeutics

Org chart

Teams

Offices

Talawar Therapeutics

Org chart

Teams

Offices

Related companies